Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3

Conditions

Carcinoma, Hepatocellular 19Carcinoma, Renal Cell 13Parkinson Disease 4, Autosomal Dominant Lewy Body 10Endometrial Neoplasms 6Neoplasms 4Biliary Tract Neoplasms 4Neuroendocrine Tumors 3Melanoma 3Liver Neoplasms 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2von Hippel-Lindau Disease 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Penile Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Kidney Neoplasms 1Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1

Interventions

lutetium Lu 177 dotatate 12Specimen Handling 6Magnetic Resonance Spectroscopy 6cabozantinib 5Everolimus 5pembrolizumab 4Nivolumab 4olaparib 3lenvatinib 3Cyclophosphamide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Phantoms, Imaging 2Octreotide 2Lutetium-177 2Ipilimumab 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2tivozanib 1surufatinib 1repotrectinib 1peposertib 1pazopanib 1entrectinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × lenvatinib × 90 days × Clear all
NCT04848337 2026-05-11

PLANE-PC

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
45 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
36 enrolled
EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Recruiting
29 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡